ChromaDex (CDXC) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
Go back to ChromaDex (CDXC) Misses Q4 EPS by 1c
March 10, 2021 9:29 AM EST
Today's Pre-Open Stock Movers:
MediciNova, Inc. (NASDAQ: MNOV) 77.6% HIGHER; announced it has partnered with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to repurpose MN-166 (ibudilast) as a potential medical countermeasure (MCM) against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). Under the Division of Research, Innovation, and Ventures (DRIVe) Repurposing Drugs in Response to Chemical Threats (ReDIRECT)... More
March 10, 2021 6:36 AM EST
ChromaDex Corp. (NASDAQ: CDXC) announced today its flagship consumer product and industry-leading NAD+ booster Tru Niagen® will be available in 3,000 Walmart retail stores across the United States beginning June 2021. ChromaDex will introduce Tru Niagen® in two packaging options for Walmart customers, which will have distinct serving sizes and price points. In addition to in-store availability, these two options will be... More
March 9, 2021 8:27 AM EST
B.Riley analyst Jeff Van Sinderen raised the price target on ChromaDex (NASDAQ: CDXC) to $18.00 (from $7.00) while maintaining a Buy rating.... More
